Multinational phase 2 trial of relacorilant plus nab-paclitaxel for recurrent, platium-resistant ovarian cancer

Outcomes for patients with platinum-resistant ovarian cancer are poor. Selective glucocorticoid receptor modulation with relacorilant may restore chemosensitivity. A multinational phase 2 trial found that addition of intermittent relacorilant to nab-paclitaxel for recurrent platinum-resistant ovarian cancer was associated with significantly improved PFS and a trend toward improved OS. Addition of continuous relacorilant was not associated with improved PFS or OS. Relacorilant was associated with minimal additional toxicity.